Global Pediatric Epilepsy Therapeutics Market 2019-2023

The global pediatric epilepsy therapeutics market is predicted to grow considerably by 2023 fueled by the emergence of biomarkers for effective pediatric epilepsy treatment. Wondering how to make the most of this thriving pediatric epilepsy therapeutics industry? Technavio’s extensive industry research report offers a detailed insight that will allow you to take full advantage of the opportunities available to you. This study provides an in-depth analysis of the market by considering the evolving demographics and consumer behavior in the global pediatric epilepsy therapeutics market. It also examines the competitive landscape and some key pediatric epilepsy therapeutic companies that include Eisai, GlaxoSmithKline, and GW Pharmaceuticals.

Let’s dissect the latest facts about the pediatric epilepsy therapeutics industry

The global pediatric epilepsy therapeutics market is expected to grow at a CAGR of almost 6% during the forecast

Pediatric epilepsy therapeutics industry growth is forecasted to accelerate massively over the next five years driven by the increasing demand for second and third-generation AEDs. The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects. Furthermore, the third-generation AEDs like eslicarbazepine acetate and lacosamide are expected to show promising impact in the treatment of pediatric epilepsy. Technavio’s pediatric epilepsy therapeutics industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Americas will be the largest driver of growth for the global pediatric epilepsy therapeutics market

More than 45% of the incremental growth of the global pediatric epilepsy therapeutics market will be driven by the Americas during the forecast period, while EMEA and APAC are predicted to make smaller yet vital contributions to the market growth. The Americas also held the largest share in the global pediatric epilepsy therapeutics market, followed by EMEA and APAC respectively. However, APAC is forecasted to generate the fastest rate of growth in the global pediatric epilepsy therapeutics market over the next five years while EMEA will register a higher CAGR than the Americas during the same period.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services. Start your 14-day FREE trial

Eisai, GlaxoSmithKline, and GW Pharmaceuticals are among the leading pediatric epilepsy therapeutic companies

The global pediatric epilepsy therapeutics market is slated to become reasonably concentrated with the presence of a few vendors who offer drugs for pediatric epilepsy treatment such as first-generation epileptics, second-generation epileptics, and third-generation epileptic drugs. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry. Many international and regional vendors are vying for their share of the global pediatric epilepsy therapeutics market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several pediatric epilepsy therapeutic companies, including:

• Eisai
• GlaxoSmithKline
• GW Pharmaceuticals
• Pfizer
• UCB

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch